{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BioXcel Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"BTAI"},"Address":{"label":"Address","value":"555 LONG WHARF DRIVE,12TH FLOOR, NEW HAVEN, Connecticut, 06511, United States"},"Phone":{"label":"Phone","value":"+1 475 238-6837"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701."},"CompanyUrl":{"label":"Company Url","value":"https://www.bioxceltherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Frank D. Yocca","title":"Chief Scientific Officer & Senior Vice President"},{"name":"Vimal D. Mehta","title":"President, Chief Executive Officer & Director"},{"name":"Vincent J. O'Neill","title":"EVP, Chief Medical & Product Development Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}